Profese online 2020, 13(1):56-64 | DOI: 10.5507/pol.2020.008

Epidemiology of atrial fibrillation

Anna Zatloukalová
Ústav zdravotnického managementu, Fakulta zdravotnických věd, Univerzita Palackého v Olomouci, Olomouc, Česká republika
Centrum vědy a výzkumu, Fakulta zdravotnických věd, Univerzita Palackého v Olomouci, Olomouc, Česká republika

Background: Atrial fibrillation is a pending rhythm disorder in the population. Its incidence and prevalence are increasing not only in the Czech Republic but also in the world. It is therefore possible that it threatens to  trust.

Objective: The aim of the communication is to acquaint healthcare professionals across this field with this topic.

Methods: A search method was used to find available words in Czech, but especially in foreign databases.

Results: In the Czech Republic there are almost 300,000 patients, in the world the number is climbing to 30  million patients and is growing every year. Age, gender, and genetic factors are not controllable risk factors. Other risk factors include obesity, metabolic syndrome, chronic kidney disease or hypertension. Warfarin is  often used in therapy of atrial fibrillation. New direct oral anticogulants are currently available: dabgatran, rivaroxaban, apixaban and darexban.

Conclusions: Fibrillation-causing illnesses, initial numbers, as your life span increases, increase your year. Many risk factors for atrial fibrillation are preventable. It is therefore appropriate to focus on the prevention of, in particular, lifestyle risk factors.

Keywords: epidemiology, atrial fibrilation, risk factors, prevention

Received: April 2020; Accepted: June 2020; Published: July 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zatloukalová, A. (2020). Epidemiology of atrial fibrillation. Profese Online, 13(1), 56-64. doi: 10.5507/pol.2020.008
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Čihák R, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Summary of the document prepared by the Czech Society of Cardiology. Cor et Vasa. [Internet]. 2016 [cited 2020 Jan 15]; 58(6):[636-683 p.]. Available from: http://www.sciencedirect.com/science/article/pii/S0010865016301047 Go to original source...
    2. Di Nisio M, Van Es N, Büller HR. Deep vein thrombosis and pulmonary embolism. Lancet. 2016;388(10063):3060-3073. Go to original source... Go to PubMed...
    3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. ESC Scientific Document Group. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart. J. 2016;37(38):2893-2962. Go to original source... Go to PubMed...
    4. Maly J, Dvorackova S, Zimcikova E, Kubena AA, Kolar J, Vlcek J, et al. Patterns in anticoagulant utilization in the Czech Republic during 2007-2017. J Thromb Thrombolysis. 2019;47(2):305-311. Go to original source... Go to PubMed...
    5. Malá-Ládová K, Patková A, Šolínová J, Alves Da Costa AF. Měření tepové frekvence v lékárnách jako nástroj pro zvyšování povědomí o fibrilaci síní v České republice - pilotní projekt: Pulse check as a tool to raise awareness of atrial fibrillation in pharmacies in the Czech Republic - a pilot project. Čes slov Rarm. 2019;68(5):198-203.
    6. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375. Go to original source... Go to PubMed...
    7. Lábrová R. Epidemiologie fibrilace síní. Kardiofórum. 2007;5(1):6-10.
    8. Lábrová R, Špinar J. Antikoagulační terapie a fibrilace síní. Kradiol Rev. 2012;14(2):79-86.
    9. Musil V. Rizikové faktory fibrilace síní. Kardiol Rev. 2010;12(3):131-133.
    10. Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet. 2015;386(9989):154-162. Go to original source... Go to PubMed...
    11. Vaupel JW. Biodemography of human ageing. Nature. 2010;464(7288):536-542. Go to original source... Go to PubMed...
    12. Lip GYH, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest. 2012;142(6):1489-1498. Go to original source... Go to PubMed...
    13. Čihák R, Heinc P, Haman L, Fiala M, Neužil P, Toman O. Fibrilace síní: Doporučený diagnostický a léčebný postup České kardiologické společnosti vypracovaný Pracovní skupinou arytmie a trvalé kardiostimulace. Cor Vasa. 2011;53(Suppl 1):27-52. Go to original source...
    14. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation. 2001;104(24):2886-2891. Go to original source... Go to PubMed...
    15. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767-1772. Go to original source... Go to PubMed...
    16. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98(8):731-733. Go to original source... Go to PubMed...
    17. Kunešová M, Hlubík P, Hainer V, et al. Obezita. Doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře. Praha: Společnost všeobecného lékařství ČLS JEP 2005.
    18. Umetani K, Kodama Y, Nakamura T, et al. High prevalence of paroxysmal atrial fibrillation and/or atrial flutter in metabolic syndrome. Circ J. 2007;71(2):252-255. Go to original source... Go to PubMed...
    19. Korantzopoulos P, Kokkoris S, Papaioannides D. The association of metabolic syndrome with atrial fibrillation: an emerging epidemiological and pathophysiological hypothesis. Cardiology. 2005;104(3):148-149. Go to original source... Go to PubMed...
    20. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation. 2008;117(10):1255-1260. Go to original source... Go to PubMed...
    21. Zatloukalová A, Janoutová J, Homza M, Machaczka O, Janout V. Epidemiologická studie nových antikoagulancií. Klin Farmakol Farm. 2018;32(2):3-7. Go to original source...
    22. Drager LF, Bortolotto LA, Lorenzi MC, et al. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med. 2005;172(5):613-618. Go to original source... Go to PubMed...
    23. Roche F, Xuong AN, Court-Fortune I, et al. Relationship among the severity of sleep apnea syndrome, cardiac arrhythmias, and autonomic imbalance. Pacing Clin Electrophysiol. 2003; 26(3):669-677. Go to original source... Go to PubMed...
    24. Kanagala R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation. 2003;107(20):2589-2594. Go to original source... Go to PubMed...
    25. Puddey IB, Rakic V, Dimmitt SB, et al. Influence of pattern of drinking on cardiovascular disease and cardiovascular risk factors - a review. Addiction. 1999;94(5):649-663. Go to original source... Go to PubMed...
    26. Koskinen P, Kupari M, Leinonen H, et al. Alcohol and new onset atrial fibrillaion: a case-control study of a current series. Br Heart J. 1987;57(5):468-473. Go to original source... Go to PubMed...
    27. Hayashi H, Omichi C, Miyauchi Y, et al. Age-related sensitivity to nicotine for inducible atrial tachycardia and atrial fibrillation. Am J Physiol Heart Circ Physiol. 2003;285(5):H2091-H2098. Go to original source... Go to PubMed...
    28. Mamun AA, Peeters A, Barendregt J, Willekens F, Nusselder W, Bonneux L, NEDCOM. The Netherlands Epidermiology and Demography Compression of Morbidity Research Group. Smoking decreases the duration of life lived with and without cardiovascular disease: a life course analysis of the Framingham Heart Study. Eur Heart J. 2004;25(5):409-415. Go to original source... Go to PubMed...
    29. Nieuwlaat R, Capucci A, Camm AJ, et al. Atrial fibrillation management: a prospective survey in ESC member countries: the EuroHeart Survey on Atrial Fibrillation. Eur Heart J. 2005;26(22):2422-2434. Go to original source... Go to PubMed...
    30. Nabauer M, Gerth A, Limbourg T, Schneider S, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11(4):423-434. Go to original source... Go to PubMed...
    31. Hutyra M, Šaňák D. Embolic ischemic strokes. Vnit Lek. 2014;60(12):1040-1049.
    32. Heinc P, Kováčik F, Moravec O, Přeček J, Táborský M. Nová doporučení pro léčbu fibrilace síní. Interní medicína pro praxi. 2013;15(2):52-58.
    33. Brown JD, Anand R, Shewale A, Jeffery C. Talbert. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation. Journal of Managed Care. 2016;22(11):1319-1329. Go to original source... Go to PubMed...
    34. Jones WS, Hellkamp AS, Halperin J, Piccini JP, Breithardt G, Singer DE, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J. 2014;35(4):242-249. Go to original source... Go to PubMed...
    35. Piccini JP, Stevens SR, Lokhnygina Y, et al. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013;61(19):1998-2006. Go to original source... Go to PubMed...
    36. Granger CHB, Alexander JH, Mcmurray JV, et al. for the aristotle committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation. Engl J Med. 2011;365(11):981-992. Go to original source... Go to PubMed...
    37. Kuan HNg, et al. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age And Ageing. 2016;45(1):77-83. Go to original source... Go to PubMed...
    38. Kvasnička J, Penka M, Kvasnička T, et al. Doporučení české společnosti pro trombózu a hemostázu České lékařské společnosti J. E. Purkyně pro bezpečnou léčbu novými perorálními antikoagulancii (NOAC) - dabigatran mexilátem, apixabanem a rivaroxabanem. Vnitř. Lék. 2015;61(6):537-546.
    39. Sjögren V, Byström B, Renlund H, et al. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: a retrospective register study. PLoS One. 2017;12(7):e0181000. Go to original source... Go to PubMed...
    40. Pollack CV, Reilly PA, Van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377(5):431-441. Go to original source... Go to PubMed...
    41. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946-952. Go to original source... Go to PubMed...
    42. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988. Go to original source... Go to PubMed...
    43. Frost L, Engholm G, Johnsen S, et al. Incident thromboembolism in the aorta and the renal, mesenteric, pelvic, and extremity arteries after discharge from the hospital with a diagnosis of atrial fibrillation. Arch Intern Med. 2001;161(2):272-276. Go to original source... Go to PubMed...
    44. Knecht S, Oelschläger C, Duning T, et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J. 2008;29(17):2125-2132. Go to original source... Go to PubMed...
    45. Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: a systematic review. Am J Med. 2006;119(5):448.e1-19. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content